Nili Peylan‐Ramu

1.3k total citations
24 papers, 956 citations indexed

About

Nili Peylan‐Ramu is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Nili Peylan‐Ramu has authored 24 papers receiving a total of 956 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Nili Peylan‐Ramu's work include Lymphoma Diagnosis and Treatment (6 papers), Acute Lymphoblastic Leukemia research (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Nili Peylan‐Ramu is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Acute Lymphoblastic Leukemia research (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Nili Peylan‐Ramu collaborates with scholars based in Israel, United States and Belgium. Nili Peylan‐Ramu's co-authors include David G. Poplack, Giovanni Di Chiro, Bruce T. Adornato, Philip A. Pizzo, Tamar Peretz, Hovav Nechushtan, Joseph Shapira, Gail Amir, M. Ulmansky and Maya Groysman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Nili Peylan‐Ramu

24 papers receiving 889 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nili Peylan‐Ramu Israel 14 327 243 240 210 157 24 956
Alfred Grovas United States 11 334 1.0× 206 0.8× 139 0.6× 225 1.1× 99 0.6× 17 737
Odile Lejars France 16 298 0.9× 328 1.3× 139 0.6× 416 2.0× 153 1.0× 28 980
Judith Kingston United Kingdom 19 322 1.0× 282 1.2× 279 1.2× 159 0.8× 68 0.4× 35 1.2k
P.N. Plowman United Kingdom 20 257 0.8× 146 0.6× 253 1.1× 95 0.5× 100 0.6× 55 1.1k
Danuta Perek Poland 17 251 0.8× 432 1.8× 249 1.0× 257 1.2× 90 0.6× 56 1.1k
E Madon Italy 19 249 0.8× 321 1.3× 234 1.0× 437 2.1× 101 0.6× 74 1.4k
Thankamma Ajithkumar United Kingdom 20 395 1.2× 133 0.5× 300 1.3× 353 1.7× 103 0.7× 65 1.2k
J. J. Mulvihill United States 12 229 0.7× 534 2.2× 633 2.6× 96 0.5× 207 1.3× 20 1.4k
Bożenna Dembowska–Bagińska Poland 17 154 0.5× 448 1.8× 218 0.9× 239 1.1× 81 0.5× 68 1.0k
L. Claude France 19 917 2.8× 267 1.1× 280 1.2× 203 1.0× 64 0.4× 105 1.6k

Countries citing papers authored by Nili Peylan‐Ramu

Since Specialization
Citations

This map shows the geographic impact of Nili Peylan‐Ramu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nili Peylan‐Ramu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nili Peylan‐Ramu more than expected).

Fields of papers citing papers by Nili Peylan‐Ramu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nili Peylan‐Ramu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nili Peylan‐Ramu. The network helps show where Nili Peylan‐Ramu may publish in the future.

Co-authorship network of co-authors of Nili Peylan‐Ramu

This figure shows the co-authorship network connecting the top 25 collaborators of Nili Peylan‐Ramu. A scholar is included among the top collaborators of Nili Peylan‐Ramu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nili Peylan‐Ramu. Nili Peylan‐Ramu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nechushtan, Hovav, et al.. (2015). A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. The Oncologist. 20(4). 366–367. 160 indexed citations
2.
Sonnenblick, Amir, Tamar Peretz, Ofer Merimsky, et al.. (2015). Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. Molecular and Clinical Oncology. 3(4). 829–832. 7 indexed citations
3.
Bar, Jair, Arnold Cyjon, Dov Flex, et al.. (2014). EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer. Lung. 192(5). 759–763. 5 indexed citations
4.
Gaze, Mark N., Tom Boterberg, Karin Dieckmann, et al.. (2010). Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study. Radiotherapy and Oncology. 97(3). 593–595. 10 indexed citations
5.
Altorki, Nasser K., Maureen E. Lane, Thomas Bauer, et al.. (2010). Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 28(19). 3131–3137. 104 indexed citations
6.
Gorodetsky, Raphael, et al.. (2004). Interactions of carboplatin with fibrin(ogen), implications for local slow release chemotherapy. Journal of Controlled Release. 102(1). 235–245. 17 indexed citations
7.
Pikarsky, Eli, et al.. (2003). The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. The Journal of Pathology. 199(4). 526–533. 58 indexed citations
8.
Amir, Gail, Josephine Issakov, Isaac Meller, et al.. (2002). Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: Correlation with clinical outcome. Human Pathology. 33(2). 170–174. 29 indexed citations
9.
Peylan‐Ramu, Nili, et al.. (2001). Orbital growth retardation in retinoblastoma survivors: Work in progress. Medical and Pediatric Oncology. 37(5). 465–470. 28 indexed citations
10.
Peylan‐Ramu, Nili, Judith Diment, Svetlana Krichevsky, et al.. (2001). Expression of EBV Encoded Nuclear Small Non-Polyadenylated RNA (EBER) Molecules in 32 Cases of Childhood Burkitt's Lymphoma from Israel. Leukemia & lymphoma. 40(3-4). 405–411. 8 indexed citations
11.
Peylan‐Ramu, Nili, Gabriel Cividalli, G. Váradi, et al.. (1999). The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Bone Marrow Transplantation. 23(9). 861–865. 14 indexed citations
12.
Friedlaender, Michael M., Yosef S. Haviv, E. Rosenmann, & Nili Peylan‐Ramu. (1998). End-Stage Renal Interstitial Fibrosis in an Adult Ten Years after Ifosfamide Therapy. American Journal of Nephrology. 18(2). 131–133. 18 indexed citations
13.
Shapira, Joseph & Nili Peylan‐Ramu. (1998). Burkitt’s Lymphoma. Oral Oncology. 34(1). 15–23. 27 indexed citations
14.
Gillis, David, et al.. (1998). Parathyroid adenoma after radiation in an 8-year-old boy. The Journal of Pediatrics. 132(5). 892–893. 4 indexed citations
15.
Slasky, B. Simon, Jacob Bar‐Ziv, Arnold I. Freeman, & Nili Peylan‐Ramu. (1997). CT appearances of involvement of the peritoneum, mesentery and omentum in Wilms' tumor. Pediatric Radiology. 27(1). 14–17. 11 indexed citations
16.
Shapira, Joseph, Nili Peylan‐Ramu, & J. Lustmann. (1995). Retrospective epidemiological study of Burkitt's lymphoma in israel and diagnosis by a conservative incisional biopsy. European Journal of Cancer Part B Oral Oncology. 31(5). 319–322. 3 indexed citations
17.
Caine, Yehezkel, et al.. (1990). Primary Burkitt's Lymphoma of the Appendix. European Journal of Pediatric Surgery. 45(4). 251–252. 6 indexed citations
18.
Peylan‐Ramu, Nili, et al.. (1989). High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 7(12). 1800–1806. 53 indexed citations
19.
Ratner, Lee, Nili Peylan‐Ramu, Robert Wesley, & David G. Poplack. (1986). Adverse prognostic influence of hepatitis b virus infection in acute lymphoblastic leukemia. Cancer. 58(5). 1096–1100. 11 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alfred Grovas Breakdown of academic impact, for papers by Odile Lejars Breakdown of academic impact, for papers by Judith Kingston Breakdown of academic impact, for papers by P.N. Plowman Breakdown of academic impact, for papers by Danuta Perek Breakdown of academic impact, for papers by E Madon Breakdown of academic impact, for papers by Thankamma Ajithkumar Breakdown of academic impact, for papers by J. J. Mulvihill Breakdown of academic impact, for papers by Bożenna Dembowska–Bagińska Breakdown of academic impact, for papers by L. Claude
Rankless by CCL
2026